Loading
A phase 1/2 trial of TT-10 in renal cell carcinoma, prostate cancer, non-small-cell lung cancer and mesothelioma, run by Portage Biotech, now recruiting.
TT-4 and TT-10 as Single Agents and in Combination in Subjects With Advanced Selected Solid Tumors and Pleural Mesothelioma is a phase 1/2 interventional study registered as NCT04969315 by Portage Biotech, with 35 participants planned, started 2023-06-23 and due to reach its primary completion in 2028-12-01. Interventions recorded: TT-10 and TT-4.
The full inclusion and exclusion criteria are on the registry record. Read 2026-10-07. Recruiting overall does not mean a particular site is open; ask the study team.
ClinicalTrials.gov data courtesy of the US National Library of Medicine.
Shares CD73 / adenosine axis, Renal cell carcinoma, Non-small-cell lung cancer and the tag pipeline.
Shares CD73 / adenosine axis, Non-small-cell lung cancer and the tag pipeline.
Shares Renal cell carcinoma, Non-small-cell lung cancer and the tag pipeline.
Shares Renal cell carcinoma, Non-small-cell lung cancer and the tag pipeline.
Shares CD73 / adenosine axis, Non-small-cell lung cancer and the tag pipeline.
Shares Renal cell carcinoma, Non-small-cell lung cancer and the tag pipeline.
Shares CD73 / adenosine axis, Non-small-cell lung cancer and the tag pipeline.
Shares Prostate cancer, Non-small-cell lung cancer and the tag pipeline.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/